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Abstract
A BRCA2 prostate cancer cluster region (PCCR) was recently proposed (c.7914 to 30)
wherein pathogenic variants (PVs) are associated with higher prostate cancer (PCa) risk
than PVs elsewhere in the BRCA2 gene. Using a prospective cohort study of 447 male
BRCA2 PV carriers recruited in the UK and Ireland from 1998 to 2016, we estimated
standardised incidence ratios (SIRs) compared with population incidences and assessed
variation in risk by PV location. Carriers of PVs in the PCCR had a PCa SIR of 8.33 (95%
confidence interval [CI] 4.46–15.6) and were at a higher risk of PCa than carriers of other, 9
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carriers had an estimated cumulative PCa risk of 44% (95% CI 23–72%) by the age of
75 yr and 78% (95% CI 54–94%) by the age of 85 yr. Our results corroborate the
existence of a PCCR in BRCA2 in a prospective cohort.
Patient summary: In this report, we investigated whether the risk of prostate cancer
for men with a harmful mutation in the BRCA2 gene differs based on where in the
gene the mutation is located. We found that men with mutations in one region of
BRCA2 had a higher risk of prostate cancer than men with mutations elsewhere in the
gene.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).
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for pathogenic variants (PVs) in BRCA2, based on a
prospective cohort of male carriers [1]. Variability in cancer
risks due to genotype-phenotype correlations may allow for
more individualised counselling and screening. We noted
that PVs within the so-called ovarian cancer cluster region
(OCCR) in exon 11 of the gene [2–4] were associated with a
lower PCa risk than other BRCA2 PVs [1,3,4]. PVs in the OCCR
have consistently been shown to be associated with an
increased ovarian cancer risk but a decreased breast cancer
risk [2,3,5,6], although the precise boundaries of the OCCR
[3,5] and the mechanisms behind this risk variation remain
uncertain. It has been proposed that the likelihood that a PV
triggers nonsense-mediated mRNA decay varies by genomic
region [7,8] so that OCCR PVs might produce a truncated or
alternatively spliced protein the capability of which to
suppress tumours varies by cancer type [2,3,5,7,8], but there
is currently no experimental support for this hypothesis
[7]. Shortly after the publication of our manuscript, Patel
and coworkers [8] proposed the existence of a prostate
cancer cluster region (PCCR) at the 30 end of BRCA2, based on
retrospective cohort data. This retrospective study reported
that men with BRCA2 PVs in the proposed PCCR have a
higher risk of PCa (hazard ratio [HR] = 1.78, 95% confidence
interval [CI] 1.25–2.52), particularly Gleason score 8 PCa
(HR = 3.11, 95% CI 1.63–5.95), than men with PVs in the
reference region c.1001 to c.7913, but did not present
estimates of the absolute PCa risk for PCCR PV carriers [8]. In
order to substantiate or refute this association, and to
provide direct estimates of the absolute risk of PCa for
carriers of BRCA2 PCCR PVs, we have reanalysed our
prospective data.
The prospective cohort comprised 447 male BRCA2 PV
carriers who were recruited to the EMBRACE study (http://
ccge.medschl.cam.ac.uk/embrace/) through clinical genet-
ics centres in the UK and Ireland between 1998 and 2016 at a
median age of 51.4 yr (interquartile range 41.5–63.6 yr). The
participants were counselled with regard to their PV.
Detailed information on the cohort and on inclusion criteria,
data collection, follow-up, and statistical analysis approach
is available in our recent publication [1]. The participants’
PVs (listed in Supplementary Table S1) were grouped on the
basis of position within the BRCA2 gene, based on the
proposed PCCR (c.7914 to 30 [8]; HGVS nomenclature
[http://varnomen.hgvs.org/]; using cDNA reference se-
quence NM_000059.3 and reference genome hg18) and
the wide definition of the OCCR (c.2831 to c.6401) [1–4]. WePlease cite this article in press as: Nyberg T, et al. . Eur Urol (202additionally considered the region bounded by c.756 and
c.1000 in which Patel and coworkers [8] found evidence of
an increased PCa risk, but due to a small sample size (n = 1)
we could not estimate the PCa risk associated with this
region. Here, we also present floating absolute risks (FARs)
[9] to enable risk comparisons between any of the
considered genomic regions.
The Anglia and Oxford Medical Research and Ethics
Committee approved the study. All participants provided
written informed consent.
Twenty-six participants developed PCa during a median
follow-up of 5.3 yr (interquartile range 2.6–8.9 yr) [1]. Car-
riers of PVs in the PCCR (n = 93) had a PCa standardised
incidence ratio (SIR) of 8.33 (95% CI 4.46–15.6), whereas
carriers of PVs elsewhere in BRCA2 (n = 354) had an SIR of
3.31 (95% CI 1.97–5.57) compared with population inci-
dences. This corresponds to a significantly higher PCa risk
associated with PVs in the PCCR than PVs not in the PCCR
(HR = 2.34, 95% CI 1.09–5.03; Table 1). Compared with PVs in
the region c.1001 to c.7913 [8], PCCR PVs were associated
with an HR of 2.09 (95% CI 0.98–4.45). As previously
reported, the SIR for carriers of PVs in the wide definition of
the OCCR (n = 178) was 2.46 (95% CI 1.07–5.64) [1], and the
risk for carriers of PCCR PVs was also significantly higher
than that for OCCR PV carriers (HR = 3.41, 95% CI 1.27–9.16).
The SIR for PVs located in the region bounded by the OCCR
and the PCCR (c.6402 to c.7913; n = 66) was estimated to be
6.14 (95% CI 2.18–17.3), and the SIR for BRCA2 PVs upstream
of the OCCR (50 to c.2830; n = 108) was 3.50 (95% CI 1.48–
8.26). The FARs for the comparison of risks across the four
regions suggested that the observed increased risk associ-
ated with PVs in the PCCR may partly be driven by the lower
risk associated with PVs in the OCCR (Table 1). The
proportional hazard assumption was violated for the model
with all genomic regions fitted (Schoenfeld residual test, p =
0.003); in line with this the corresponding Kaplan-Meier
plot indicated that the risks might be similar between OCCR
and PCCR PV carriers at younger ages but deviate at older
ages. PCCR PV carriers had an estimated cumulative PCa risk
of 44% (95% CI 23–72%) by the age of 75 yr and 78% (95% CI
54–94%) by 85 yr. After omitting the first 6 mo of follow-up
to assess the possible effect of screening-associated
diagnoses of indolent PCa, the corresponding estimates
were 41% (95% CI 20–73%) and 69% (95% CI 42–91%),
respectively (Fig. 1).
The difference in PCa risk for PVs in the PCCR versus that
in the OCCR remained statistically significant after adjusting0), https://doi.org/10.1016/j.eururo.2020.05.005
Table 1 – Prostate cancer risk by location of BRCA2 pathogenic variant.
PV location N Person
years
Observed
events
Incidence rate
per 1000 person
years (95% CI)
Expected
events
SIR (95% CI) HR (95% CI) FAR (95% CI)
Compared with non-PCCR PVs
Non-PCCR (50 to c.7913) 354 2029.8 15 7.39 (4.45–12.3) 4.53 3.31 (1.97–5.57) Reference
PCCR (c.7914 to 30) 93 524.6 11 21.0 (11.4–38.7) 1.32 8.33 (4.46–15.6) 2.34 (1.09–5.03)
Compared with OCCR PVs
50 to c.2830 108 625.8 5 7.99 (3.37–19.0) 1.43 3.50 (1.48–8.26) 1.72 (0.50–5.94) 1.72 (0.70–4.24)
OCCR (c.2831 to c.6401) a 178 1054.4 6 5.69 (2.54–12.8) 2.44 2.46 (1.07–5.64) Reference 1.00 (0.43–2.33)
c.6402 to c.7913 66 338.8 4 11.8 (4.29–32.5) 0.65 6.14 (2.18–17.3) 3.23 (0.79–13.2) 3.23 (1.15–9.11)
PCCR (c.7914 to 30) 93 524.6 11 21.0 (11.4–38.7) 1.32 8.33 (4.46–15.6) 3.41 (1.27–9.16) 3.41 (1.96–5.95)
Indeterminable 2
CI = confidence interval; FAR = floating absolute risk; HR = hazard ratio; OCCR = ovarian cancer cluster region; PCCR = prostate cancer cluster region;
PV = pathogenic variant; SIR = standardised incidence ratio.
a Detailed results for carriers of PVs in the OCCR are available in a previous publication [1].
E U R O P E A N U R O L O G Y X X X ( 2 0 1 9 ) X X X – X X X 3
EURURO-8874; No. of Pages 4for family history of PCa (number of first- and second-
degree relatives diagnosed with PCa; adjusted HR = 3.00,
95% CI 1.06–8.54) or geographical location (adjusted HR =
3.79, 95% CI 1.41–10.2). This difference remained similar
after omitting the first 6 mo of follow-up (HR = 3.96, 95% CI
1.18–13.3), related individuals (HR = 4.29, 95% CI 1.30–14.2),
and carriers of PVs in the region c.756 to c.1000 (HR = 3.42,
95% CI 1.27–9.18) or missense variants (HR = 3.76, 95% CI
1.36–10.4). When carriers of the Ashkenazi founder PV
c.5946delT (n = 42), which is located in the OCCR, was
omitted, the difference in PCa risk between PCCR and OCCR
PV carriers was not statistically significant, but the HR
estimate was of similar magnitude (HR = 2.89, 95% CI 0.98–
8.53; Supplementary Table S2).
We did not observe a higher risk of Gleason score 8 PCa
for PVs in the PCCR than for PVs not in the PCCR (HR = 0.87,
95% CI 0.12–6.34) or in the region c.1001 to c.7913Fig. 1 – Absolute prostate cancer risk (A) by location of BRCA2 pathogenic varia
initiated 6 mo after study entry. The number at risk at each age is shown abov
participants are at risk. OCCR = ovarian cancer cluster region; PCCR = prostate c
Please cite this article in press as: Nyberg T, et al. . Eur Urol (202(HR = 0.79, 95% CI 0.11–5.69). However, the HRs did not
differ significantly from those for Gleason score 7 PCa
(PCCR vs non-PCCR: HR = 3.32, 95% CI 1.25–8.84; test for
heterogeneity, p = 0.052; PCCR vs c.1001 to c.7913: HR =
2.94, 95% CI 1.11–7.80; test for heterogeneity, p = 0.088).
Our results corroborate the observation that carriers of
PVs in the PCCR of the BRCA2 gene [8] are at a higher risk of
PCa than other BRCA2 PV carriers. Patel and coworkers [8]
reported an HR of 1.78 (95% CI 1.25–2.52) compared with
PVs in the region c.1001 to c.7913, consistent with our HR
estimate of 2.09 (95% CI 0.98–4.45). Our findings do not
support a stronger association with a more aggressive
phenotype, but these estimates were based on a small
number of cases and the associated CIs are wide. PV carriers
may receive enhanced screening, which may lead to biases
in comparisons against the population incidence [1]. How-
ever, current screening practices do not differ by BRCA2 PVnt and (B) by location of BRCA2 pathogenic variant and with follow-up
e the x-axis. The curves are truncated at ages when fewer than five
ancer cluster region.
0), https://doi.org/10.1016/j.eururo.2020.05.005
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comparisons between the BRCA2 genomic regions. A much
larger cohort of unaffected carriers with longer follow-up is
required to provide more precise PV-specific risk estimates
and to further clarify whether the observed variation in risk
reflects lower risks associated with PVs outside the OCCR
and PCCR than the risk associated with PCCR PVs, or solely a
lower risk associated with PVs in the OCCR.
Author contributions: Tommy Nyberg had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Antoniou, Nyberg, Easton.
Acquisition of data: Frost, Barrowdale, Bancroft, Easton, Eeles, Evans,
Tischkowitz, Adlard, Ahmed, Barwell, Brady, Brewer, Cook, Davidson,
Donaldson, Eason, Gregory, Henderson, Izatt, Kennedy, Miller, Morrison,
Murray, Ong, Porteous, Pottinger, Rogers, Side, Snape, Tripathi, Walker.
Analysis and interpretation of data: Nyberg, Antoniou, Easton.
Drafting of the manuscript: Nyberg, Antoniou, Easton.
Critical revision of the manuscript for important intellectual content: Evans,
Frost, Barrowdale, Bancroft, Eeles, Tischkowitz, Adlard, Ahmed, Barwell,
Brady, Brewer, Cook, Davidson, Donaldson, Eason, Gregory, Henderson,
Izatt, Kennedy, Miller, Morrison, Murray, Ong, Porteous, Pottinger,
Rogers, Side, Snape, Tripathi, Walker.
Statistical analysis: Nyberg, Antoniou, Easton.
Obtaining funding: Easton, Antoniou, Eeles, Evans.
Administrative, technical, or material support: Frost, Barrowdale, Bancroft.
Supervision: Antoniou, Tischkowitz.
Other: None.
Financial disclosures: Tommy Nyberg certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: None.
Funding/Support and role of the sponsor: This work was supported by
Cancer Research UK grants C12292/A20861 and C12292/
A22820. EMBRACE was supported by Cancer Research UK grants
C1287/A23382 and C1287/A26886. D. Gareth Evans is supported by a
National Institute for Health Research grant to the Biomedical Research
Centre, Manchester (IS-BRC-1215-20007). Rosalind Eeles is supported by
Cancer Research UK grant C5047/A8385, and by National Institute forPlease cite this article in press as: Nyberg T, et al. . Eur Urol (202Health Research support to the Biomedical Research Centre at The
Institute of Cancer Research and The Royal Marsden NHS Foundation
Trust.
Acknowledgements: We thank all the participants in the EMBRACE
study. The data used in the analysis are available to other researchers
upon request to the EMBRACE study coordinators (https://ccge.medschl.
cam.ac.uk/embrace/).
Appendix A. Supplementary data
Supplementary material related to this article can be
found, in the online version, at doi:https://doi.org/10.1016/j.
eururo.2020.05.005.
References
[1] Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male
BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur
Urol 2020;77:24–35.
[2] Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and
ovarian cancer associated with different germline mutations of the
BRCA2 gene. Nat Genet 1997;15:103–5.
[3] Thompson D, Easton D. Variation in cancer risks, by mutation posi-
tion, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410–9.
[4] van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in
BRCA2 families: estimates for sites other than breast and ovary. J Med
Genet 2005;42:711–9.
[5] Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of
BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
JAMA 2015;313:1347–61.
[6] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast,
ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mu-
tation carriers. JAMA 2017;317:2402–16.
[7] Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian
SV, Mazoyer S. Does nonsense-mediated mRNA decay explain the
ovarian cancer cluster region of the BRCA2 gene? Oncogene
2006;25:323–8.
[8] Patel VL, Busch EL, Friebel TM, et al. Association of genomic domains
in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.
Cancer Res 2020;80:624–38.
[9] Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to
relative risk in survival and case-control analysis avoiding an arbi-
trary reference group. Stat Med 1991;10:1025–35.0), https://doi.org/10.1016/j.eururo.2020.05.005
